NantKwest (NASDAQ: NK) and ImmunityBio reported early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled in its QUILT trials.
The company said that the trial validates the theory that survival rates could be improved without high-dose chemotherapy by orchestrating natural killer and T-cell therapy.
The trials explored the idea that by activating the patient’s own immune system, a paradigm change in cancer therapy could evolve to eradicate cancer cells without high-dose chemotherapy.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“The initial results of these Cancer Moonshot trials combining immunotherapy molecules—including Abraxane from Celgene, haNK from NantKwest, Anktiva from ImmunityBio, and a PD-L1 inhibitor Avelumab from Pfizer—provided promising early data that a doubling of median overall survival rate in patients with advanced metastatic disease across multiple tumour types was possible,” said Patrick Soon-Shiong, Chairman, and CEO of ImmunityBio.
The interim study results showed cancer Moonshot QUILT trials of haNK combined with PD-L1 inhibitor avelumab were completed in 2019, the median overall survival rate more than doubled, and complete remission was achieved when replacing haNK and PD-L1 inhibitor avelumab with PD-L1 t-haNK.
On December 21st NantKwest and ImmunityBio struck a reverse merger deal that is expected to close during Q1 2021, with the company being listed on the Nasdaq under the ticker symbol IBRX.
NantKwest shares are up 32.61% premarket, priced at $19.60.
